Arrowhead Pharmaceuticals Inc (ARWR)
Profitability ratios
Return on sales
| Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | -3,322.70% | -723.08% | -372.88% | 34.21% | 55.65% | 56.85% | 56.85% | 54.53% | 46.36% | 45.71% | 54.08% | 28.65% | 37.71% | 57.05% | 56.72% | 51.69% | 54.41% | 67.55% | 75.40% | 85.82% |
| Operating profit margin | -16,927.06% | -3,803.75% | -1,891.07% | -180.08% | -91.01% | -73.38% | -56.29% | -56.52% | -73.39% | -63.84% | -44.99% | -130.38% | -107.77% | -124.74% | -132.80% | -140.73% | -105.87% | -27.01% | 0.82% | 27.75% |
| Pretax margin | -16,960.29% | -3,753.12% | -1,881.35% | -178.85% | -89.89% | -71.77% | -54.68% | -54.15% | -70.83% | -61.58% | -42.44% | -126.70% | -101.85% | -116.97% | -122.97% | -128.52% | -96.09% | -19.60% | 6.98% | 32.67% |
| Net profit margin | -16,882.37% | -3,744.17% | -1,879.17% | -178.52% | -91.13% | -73.62% | -56.10% | -55.51% | -72.39% | -61.59% | -42.44% | -126.70% | -101.85% | -116.97% | -122.97% | -128.52% | -96.09% | -19.74% | 6.86% | 32.56% |
Arrowhead Pharmaceuticals Inc has shown fluctuating profitability margins over the past few quarters. The gross profit margin, which indicates the efficiency of the company's production and pricing strategy, has been highly negative recently, reflecting challenges in generating profits from its operations.
Similarly, the operating profit margin, indicating the company's ability to control operating expenses, has been significantly negative, highlighting operating inefficiencies and high costs relative to its revenue in recent periods.
The pretax margin and net profit margin, which represent the company's overall profitability before and after taxes, respectively, have also been negative, indicating that Arrowhead Pharmaceuticals Inc has been experiencing substantial losses.
Overall, these profitability ratios suggest that the company has been facing significant financial challenges and inefficiencies in its operations, impacting its ability to generate profits and maintain a sustainable business performance.
Return on investment
| Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | -52.74% | -61.92% | -49.60% | -47.81% | -26.78% | -22.68% | -16.91% | -17.65% | -25.80% | -21.22% | -16.85% | -29.49% | -20.99% | -18.27% | -15.64% | -22.51% | -17.83% | -6.01% | 0.20% | 7.72% |
| Return on assets (ROA) | -52.60% | -60.95% | -49.29% | -47.39% | -26.81% | -22.76% | -16.85% | -17.33% | -25.44% | -20.47% | -15.89% | -28.66% | -19.83% | -17.13% | -14.48% | -20.55% | -16.18% | -4.39% | 1.70% | 9.06% |
| Return on total capital | -101.48% | -159.55% | -92.66% | -172.38% | -67.87% | -44.82% | -31.00% | -39.22% | -43.23% | -34.24% | -25.48% | -50.42% | -36.46% | -30.73% | -26.56% | -24.72% | -20.17% | -6.77% | 0.23% | 9.08% |
| Return on equity (ROE) | -323.27% | -162.95% | -97.31% | -185.04% | -75.65% | -49.64% | -33.62% | -40.98% | -44.18% | -33.91% | -24.72% | -49.12% | -34.45% | -28.82% | -24.60% | -22.58% | -18.31% | -4.95% | 1.93% | 10.65% |
Arrowhead Pharmaceuticals Inc's profitability ratios have exhibited significant fluctuations over the past few quarters.
- Operating return on assets (Operating ROA) has shown a downward trend, indicating that the company's operating profits generated from its assets have decreased.
- Return on assets (ROA) has also followed a similar downward trajectory, suggesting decreasing profitability relative to total assets.
- Return on total capital has been notably negative, signifying that the company's return on the total invested capital has been insufficient and, in some periods, highly negative.
- Return on equity (ROE) has shown a volatile pattern with substantial negative values, highlighting the company's struggle to generate profits for its shareholders relative to their equity investments.
Overall, the profitability ratios of Arrowhead Pharmaceuticals Inc reflect fluctuating performance and challenges in generating satisfactory returns from its assets, capital, and equity. Further analysis and exploration of the company's financial strategies may be needed to address these issues and improve profitability.